Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

onths ended September 30, 2010 were $37.6 million and $114.6 million, respectively, compared to $37.2 million and $105.2 million for the same periods in 2009.  

Net Loss from Continuing Operations Attributable to Isis Pharmaceuticals, Inc. Common StockholdersNet loss from continuing operations for the three and nine months ended September 30, 2010 was $12.5 million and $47.3 million, respectively, compared to $11.6 million and $15.2 million for the same periods in 2009.  The increase in Isis' net loss from continuing operations for the nine months was primarily due to the following:

  • $22.5 million increase in net operating loss, excluding Regulus, as described above;
  • $3.4 million increase in Isis' share of Regulus' net loss;
  • $2.7 million decrease in investment income due to a lower average return on investments resulting from the current market conditions and a lower average cash balance; and
  • $880,000 non-cash loss that Isis recognized in 2010 related to the impairment of its equity investment in Antisense Therapeutics Limited compared to a $2.5 million gain in 2009 from the sale of OncoGenex common stock that Isis owned.

  • Net Income (Loss)Isis reported a net loss of $12.5 million and $47.3 million for the three and nine months ended September 30, 2010, respectively, compared to a net loss of $11.6 million for the three months ended September 30, 2009 and net income of $171.9 million for the nine months ended September 30, 2009.  Basic and diluted net loss per share for the three and nine months ended September 30, 2010 was $0.13 per share and $0.48 per share, respectively, compared to basic and diluted net loss per share of $0.12 for the three months ended September 30, 2009 and net income per share of $1.75 for the nine months ended September 30, 2009.  Net income and net income per share for the first nine months of 2009 primarily consisted of the $187.2 m
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
    (Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
    (Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
    Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
    ... Tenn. , Jan. 20 Cumberland Pharmaceuticals Inc. ( ... ) Injection, an intravenous form of ibuprofen, to Haitian relief effort. ... for the treatment of pain and reduction of fever in ... continue to deteriorate, Caldolor is expected to help those suffering from ...
    ... , , LOS ANGELES , ... that it has joined forces with New Jersey -based ... create the nation,s first IVF insurance program. The Assisted Reproduction ... financial solutions for the ever-rising costs of In Vitro Fertilization ...
    Cached Medicine Technology:Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 2Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 3New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 2New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 3
    (Date:8/29/2014)... 2014 Healthpointe is proud to welcome ... Rodas will be practicing out of Healthpointe’s newest office ... of Healthpointe’s orthopedic team, Dr. Rodas is ... board-certified in occupational medicine. , Among Dr. Rodas’ ... Director of Raytheon, the world-class defense and aerospace company. ...
    (Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
    (Date:8/29/2014)... August 29, 2014 Pursuing its deepest ... set to unveil a stunning new design that promises ... figures, the highly notable surrogacy platform has witnessed a ... over 13,000 visitors a month, the FindSurrogateMother.com community is ... toward one common goal — the precious gift of ...
    (Date:8/29/2014)... trials based on administering antidepressants for acute and ... trials are needed to determine whether these drugs ... regular basis., Dr. Ian Gilron, a professor and ... of Anesthesiology, and his team of seven researchers ... of antidepressants for pain relief post-surgery would work ...
    (Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
    Breaking Medicine News(10 mins):Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
    ... and global IT giant Tata Consultancy Services (TCS) have ... a global drug development center in Mumbai. ... variety of services in clinical research, including clinical data ... ,"GSK has chosen to partner with TCS because of ...
    ... official figures.// ,Statistics for 2006 show ... which protects against measles, mumps and rubella, as against the national ... is an increase from the previous year, when the figure was ... 1988, but levels of uptake began to decline after 1998 when ...
    ... decided to crackdown on unethical doctors who accept gifts from ... entrance. ,This move follows the rocketing costs ... such tests. , According to the new law ... up to 5 years in jail, in terms of prosecution ...
    ... of persons infected with deadly viruses such as HIV and ... understand how. // , An independent inquiry is soon ... by almost 2000 hemophilia patients, via blood transfusions, in what ... of UK’s National Health Services. , The ...
    ... the “triple negative” type are destructive and lethal, and tend ... novel// study Published in the May 1, 2007 issue of ... occur commonly among women who are African American and Hispanic, ... socioeconomic status (SES). The study also showed that triple negative ...
    ... found that the most potent cholesterol-lowering drug is ... blood vessels that can lead to atherosclerosis. ... arteries compared to a placebo,” said John R.Crouse, ... at Wake Forest University School of Medicine. “The ...
    Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:Inquiry into Past NHS Treatment Disaster 2Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis 2
    Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
    TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
    The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
    ... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
    Medicine Products: